VIENNA, Va., Sept. 17 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(AMEX: CVM) announces that its Chief Executive Officer, Geert Kersten, is a
featured presenter at the Biotech/Pharma/Healthcare On-line Forum. The
webcast presentation is scheduled for Tuesday, September 18, 2007 at 9:30
a.m. (Eastern Daylight Time) and can be accessed via the Internet at
CEL-SCI's website http://www.cel-sci.com or
http://www.investorcalendar.com/ClientPage.asp?ID=119627. If you are unable
to participate during the live webcast, the call will be available for
replay.
CEL-SCI Corporation is developing products that empower immune
defenses. Its lead product is Multikine(R). In Phase II clinical trials
Multikine was shown to be safe and well-tolerated, and to improve the
patients' overall survival by 33% at a median of three and a half years
following surgery. The U.S. Food and Drug Administration (FDA) gave the
go-ahead for a Phase III clinical trial with Multikine in January 2007 and
granted orphan drug status to Multikine in the neoadjuvant therapy of
squamous cell carcinoma (cancer) of the head and neck in May 2007.
Multikine, a patented defined mixture of naturally derived cytokines,
is the first immunotherapeutic agent in a new class of drugs called "Immune
SIMULATORS". Immune SIMULATORS simulate the way our natural immune system
acts in defending us against cancer. As opposed to other immunotherapies
which are designed to target a single or limited number of specific
antigens or molecules, Immune SIMULATORS are multi-targeted; they
simultaneously cause a direct and targeted killing of the specific tumor
cells and they activate the immune system to produce a stronger anti-tumor
attack on multiple fronts.
Multikine is also the first immunotherapeutic agent being developed as
a first-line standard of care treatment for cancer. It is administered
prior to any other cancer therapy because that is the period when the
anti-tumor immune response can still be fully activated. Once the patient
has advanced disease, or had surgery or has received radiation and/or
chemotherapy, the immune system is severely weakened and is less able to
mount an effective anti-tumor immune response. Other immunotherapies are
administered after the patient has received chemotherapy and/or radiation
therapy, which can limit their effectiveness.
The Company has operations in Vienna, Virginia and Baltimore, Maryland.
CEL-SCI's other products, which are currently in pre-clinical stage, have
shown protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
